A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.

Caroline Aspord 1 Julie Charles 1 Marie-Thérèse Leccia 1, 2 David Laurin 1 Marie-Jeanne Richard 1, 3 Laurence Chaperot 1, * Joël Plumas 4
* Auteur correspondant
1 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
2 Département Pluridisciplinaire de Médecine, Dermatologie
3 Département de cancérologie et radiothérapie
4 INSERM U823, équipe 9 (Immunobiologie et Immunothérapie des Cancers)
INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
Abstract : BACKGROUND: The development of effective cancer vaccines still remains a challenge. Despite the crucial role of plasmacytoid dendritic cells (pDCs) in anti-tumor responses, their therapeutic potential has not yet been worked out. We explored the relevance of HLA-A*0201 matched allogeneic pDCs as vectors for immunotherapy. METHODS AND FINDINGS: Stimulation of PBMC from HLA-A*0201(+) donors by HLA-A*0201 matched allogeneic pDCs pulsed with tumor-derived peptides triggered high levels of antigen-specific and functional cytotoxic T cell responses (up to 98% tetramer(+) CD8 T cells). The pDC vaccine demonstrated strong anti-tumor therapeutic in vivo efficacy as shown by the inhibition of tumor growth in a humanized mouse model. It also elicited highly functional tumor-specific T cells ex-vivo from PBMC and TIL of stage I-IV melanoma patients. Responses against MelA, GP100, tyrosinase and MAGE-3 antigens reached tetramer levels up to 62%, 24%, 85% and 4.3% respectively. pDC vaccine-primed T cells specifically killed patients' own autologous melanoma tumor cells. This semi-allogeneic pDC vaccine was more effective than conventional myeloid DC-based vaccines. Furthermore, the pDC vaccine design endows it with a strong potential for clinical application in cancer treatment. CONCLUSIONS: These findings highlight HLA-A*0201 matched allogeneic pDCs as potent inducers of tumor immunity and provide a promising immunotherapeutic strategy to fight cancer.
Type de document :
Article dans une revue
PLoS ONE, Public Library of Science, 2010, 5 (5), pp.e10458. 〈10.1371/journal.pone.0010458〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00484505
Contributeur : Laurence Chaperot <>
Soumis le : mardi 18 mai 2010 - 15:13:29
Dernière modification le : mercredi 10 janvier 2018 - 10:12:02
Document(s) archivé(s) le : jeudi 16 septembre 2010 - 14:06:24

Fichiers

Aspord_-_PLoS_One_supplementar...
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

U823 | UGA

Citation

Caroline Aspord, Julie Charles, Marie-Thérèse Leccia, David Laurin, Marie-Jeanne Richard, et al.. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.. PLoS ONE, Public Library of Science, 2010, 5 (5), pp.e10458. 〈10.1371/journal.pone.0010458〉. 〈inserm-00484505〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

355

Téléchargements de fichiers

260

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD